| scholarly article | Q13442814 |
| P50 | author | Joanna Szczepanek | Q57339985 |
| P2860 | cites work | Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses. | Q37829956 |
| Epigenetic regulation of miRNA genes in acute leukemia. | Q37965026 | ||
| MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). | Q38001654 | ||
| Predicting relapse risk in childhood acute lymphoblastic leukaemia | Q38117685 | ||
| Pharmacogenetic biomarkers for predicting drug response. | Q38214388 | ||
| Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia | Q38301992 | ||
| Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities | Q38526930 | ||
| MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. | Q38701393 | ||
| miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia | Q38725046 | ||
| RETRACTED: miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia | Q38904114 | ||
| miRNA nanotherapeutics for cancer | Q38999082 | ||
| MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene | Q39093042 | ||
| Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL. | Q39106254 | ||
| Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. | Q39120062 | ||
| Genetic Basis of Acute Lymphoblastic Leukemia | Q39180500 | ||
| Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia | Q39292054 | ||
| Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. | Q39582812 | ||
| Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia | Q39647847 | ||
| Epigenetic regulation of microRNAs in acute lymphoblastic leukemia | Q39891863 | ||
| miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. | Q40090728 | ||
| MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia | Q40542758 | ||
| MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. | Q41316598 | ||
| MicroRNAs as newer therapeutic targets: A big hope from a tiny player | Q41547602 | ||
| Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia | Q41653568 | ||
| MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status | Q41908916 | ||
| Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. | Q42096217 | ||
| miR-590 promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia by inhibiting RB1. | Q42361190 | ||
| MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia | Q42724150 | ||
| Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia | Q43467395 | ||
| Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays | Q43514458 | ||
| MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia | Q43531486 | ||
| The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. | Q43566991 | ||
| High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia | Q44001281 | ||
| Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia | Q46679788 | ||
| MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis | Q47100861 | ||
| A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. | Q47263006 | ||
| miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia | Q47651906 | ||
| MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. | Q48104779 | ||
| miR-9 is a tumor suppressor in pediatric AML with t(8;21). | Q48336259 | ||
| Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. | Q48540669 | ||
| MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia. | Q48542569 | ||
| Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia. | Q49824995 | ||
| MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells | Q49977636 | ||
| Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia | Q50267725 | ||
| MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. | Q52598734 | ||
| MicroRNA-155 expression and function in AML: An evolving paradigm. | Q52618819 | ||
| Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia. | Q52817300 | ||
| miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM. | Q52934924 | ||
| miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia. | Q53222102 | ||
| B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. | Q53271931 | ||
| Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. | Q54338303 | ||
| Differential expression of specific microRNA and their targets in acute myeloid leukemia. | Q54430645 | ||
| Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. | Q54569630 | ||
| Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia. | Q54974772 | ||
| New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia | Q57821013 | ||
| miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia | Q58558606 | ||
| MicroRNA Expression Profiles Discriminate Childhood T- from B-Acute Lymphoblastic Leukemia | Q58612857 | ||
| Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia | Q58616811 | ||
| FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia | Q64008554 | ||
| Genotypic classification of childhood acute lymphoid leukemia | Q77414608 | ||
| Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale | Q82660122 | ||
| Prognostic value of miR-29a expression in pediatric acute myeloid leukemia | Q84976426 | ||
| [Expression Analysis and Epigenetics of MicroRNA let-7b in Acute Lymphoblastic Leukemia] | Q86981175 | ||
| Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001 | Q89239783 | ||
| MicroRNA delivery through nanoparticles | Q90772062 | ||
| The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy | Q91317286 | ||
| How advanced are we in targeting novel subtypes of ALL? | Q91520479 | ||
| MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia | Q92418999 | ||
| Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia | Q21144312 | ||
| Human MicroRNA targets | Q21563637 | ||
| Predicting cancer drug response by protoeomic profiling | Q23924005 | ||
| miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
| Accumulation of miR-155 and BIC RNA in human B cell lymphomas | Q24556523 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| MiR-15a and miR-16-1 cluster functions in human leukemia | Q24647555 | ||
| MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia | Q24655915 | ||
| miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements | Q24656666 | ||
| CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control | Q24676449 | ||
| Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression | Q24681466 | ||
| Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis | Q24798477 | ||
| Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine | Q26799238 | ||
| RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures | Q27851839 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets | Q27860792 | ||
| MicroRNAs: small RNAs with a big role in gene regulation | Q27860896 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Vertebrate microRNA genes | Q28181605 | ||
| MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia | Q28241703 | ||
| MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia | Q28272533 | ||
| Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression | Q28283082 | ||
| Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth | Q28303669 | ||
| Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation | Q28308183 | ||
| Perspectives on the causes of childhood leukemia | Q28391712 | ||
| miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells | Q28473023 | ||
| MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways | Q28486136 | ||
| Regulation of progenitor cell proliferation and granulocyte function by microRNA-223 | Q28510667 | ||
| Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks | Q28539028 | ||
| microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells | Q29619307 | ||
| microRNAs as oncogenes and tumor suppressors | Q29619907 | ||
| BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas | Q29622911 | ||
| MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia | Q30886103 | ||
| Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway | Q33305776 | ||
| Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia | Q33395151 | ||
| Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis | Q33573515 | ||
| Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 | Q33611301 | ||
| High-risk childhood acute lymphoblastic leukemia | Q33622837 | ||
| Childhood leukaemia | Q33808971 | ||
| miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group | Q33872395 | ||
| A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia | Q33889001 | ||
| Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. | Q33909896 | ||
| miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias | Q33957558 | ||
| miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia | Q33982491 | ||
| MicroRNA miR-125a controls hematopoietic stem cell number | Q34069509 | ||
| Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. | Q34106877 | ||
| A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL | Q34217173 | ||
| MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia | Q34251541 | ||
| Identification of hsa-miR-335 as a prognostic signature in gastric cancer | Q34339643 | ||
| MicroRNA miR-125b causes leukemia | Q34411303 | ||
| Complete characterization of the microRNAome in a patient with acute myeloid leukemia | Q34450485 | ||
| Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy | Q34468836 | ||
| Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q34477821 | ||
| Epidemiology of childhood acute myeloid leukemia | Q34647168 | ||
| Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate | Q34685280 | ||
| The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions | Q34687627 | ||
| Biology, risk stratification, and therapy of pediatric acute leukemias: an update | Q34764504 | ||
| MicroRNA expression in cytogenetically normal acute myeloid leukemia | Q34775265 | ||
| Cytogenetics and molecular genetics of acute lymphoblastic leukemia. | Q34797842 | ||
| Definition of cure in childhood acute myeloid leukemia. | Q34809196 | ||
| MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells | Q35009701 | ||
| High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia | Q35172553 | ||
| miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies | Q35515926 | ||
| Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia | Q35596909 | ||
| A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia | Q35845024 | ||
| Predicting drug response based on gene expression | Q35872206 | ||
| Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling | Q35943366 | ||
| Blood-Based Circulating MicroRNAs are Potential Diagnostic Biomarkers for Leukemia: Result from a Meta-Analysis. | Q35944233 | ||
| Predicting drug response and toxicity based on gene polymorphisms | Q36125130 | ||
| Overexpression and knockout of miR-126 both promote leukemogenesis | Q36193187 | ||
| Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia | Q36248867 | ||
| Molecular genetics of acute lymphoblastic leukemia | Q36254588 | ||
| Genomic assessment of pediatric acute leukemia | Q36273597 | ||
| Modern diagnostics in acute leukemias | Q36280666 | ||
| MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia | Q36288982 | ||
| Molecular genetics of B-precursor acute lymphoblastic leukemia | Q36290242 | ||
| Childhood acute lymphoblastic leukemia in the age of genomics | Q36347513 | ||
| MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. | Q36366621 | ||
| Genomic approaches in acute leukemia | Q36413275 | ||
| Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia | Q36464554 | ||
| Approaches to microRNA discovery | Q36493253 | ||
| Prediction of human microRNA targets | Q36587289 | ||
| Diverse functions of miR-125 family in different cell contexts | Q36594402 | ||
| Genomics and proteomics: emerging technologies in clinical cancer research. | Q36610134 | ||
| Oncomirs: the potential role of non-coding microRNAs in understanding cancer | Q36782569 | ||
| Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. | Q36926841 | ||
| MiR-134-Mbd3 axis regulates the induction of pluripotency | Q36942365 | ||
| Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation | Q36946531 | ||
| Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). | Q36992190 | ||
| OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer | Q37059796 | ||
| Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients | Q37065843 | ||
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study | Q37119445 | ||
| MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways | Q37235553 | ||
| Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years | Q37271941 | ||
| Identifying miRNAs, targets and functions. | Q37497803 | ||
| miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. | Q37694685 | ||
| Recent research advances in childhood acute lymphoblastic leukemia | Q37815272 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 348-369 | |
| P577 | publication date | 2020-06-01 | |
| P1433 | published in | World journal of clinical oncology | Q27723540 |
| P1476 | title | Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review | |
| P478 | volume | 11 |
Search more.